chufangao/CTO huggingface dataset:
Clinical trial NCT03761134: Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Chinese Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone or Metformin in Combination With Sulfonylurea
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies.
Enrollment: 377.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-30
Primary completion date: 2020-04-29
Completion date: 2020-04-29
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04590495: The Effects of Cannabidiol on the Driving Ability of Healthy Adults
Official title: The Effects of Cannabidiol on the Driving Ability of Healthy Adults: a Clinical Trial
Sponsor: West Virginia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-01
Primary completion date: 2021-12-01
Completion date: 2021-12-01
Limitations and caveats: Only one dosage of CBD was utilized, and this dose may not reflect normal use of CBD. Participants were recruited from a university so results may not be generalizable to the general population. Previous studies have shown that CBD's max absorption occurs 2-5 hours post-consumption. To balance participant burden, a two-hour waiting period between dosing and simulation was chosen. It is possible that max absorption and full effect of the drug was not reached amongst some participants.
Plan to share individual participant data: NO
IPD sharing description: We do not plan to share these data.
Clinical trial NCT04231331: Ertugliflozin for Functional Mitral Regurgitation
Official title: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy of Ertugliflozin on Reduction of Mitral Regurgitation in Patients With Functional Mitral Regurgitation Secondary to Left Ventricular Dysfunction
Acronym: EFFORT
Sponsor: Asan Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 128.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-04
Primary completion date: 2023-11-15
Completion date: 2023-11-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03689894: Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT
Official title: Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant
Sponsor: Dartmouth-Hitchcock Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Insufficient accrual
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-11
Primary completion date: 2021-09-20
Completion date: 2021-09-20
Plan to share individual participant data: NO
Clinical trial NCT04212377: Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients
Official title: An Exploratory Study: Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients
Acronym: DECENDO
Sponsor: Radboud University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-08
Primary completion date: 2021-03-09
Completion date: 2021-03-09
Plan to share individual participant data: NO
Clinical trial NCT03886649: Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Official title: Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient Funding
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-04
Primary completion date: 2021-05-10
Completion date: 2022-03-08
Clinical trial NCT01848639: ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
Official title: ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
Acronym: ALCHEMIST
Sponsor: University Hospital, Brest (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 823.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-06-30
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: YES
IPD sharing description: Statistical Analysis Plan
Clinical trial NCT05545319: A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
Official title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID-19 IN HOSPITALIZED PARTICIPANTS WHO ARE IMMUNOCOMPROMISED OR AT INCREASED RISK FOR SEVERE COVID-19 OUTCOMES
Acronym: EPIC-HOS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Termination due to challenges related to the operational feasibility of the study, taking into account the current epidemiology and declining hospitalization rates for severe COVID-19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-12-13
Primary completion date: 2023-09-21
Completion date: 2024-01-06
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05250583: Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis
Official title: Use of a Double Amniotic Membrane Inserted in a Ring of Umbilical Vessels With Wharton's Jelly, Tissues Treated by the AMTRIX Process, in the Treatment of Keratitis Resisting Healing Medical Treatment
Sponsor: TBF Genie Tissulaire (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual rate
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-29
Primary completion date: 2021-01-07
Completion date: 2021-01-07
Clinical trial NCT04156828: Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
Official title: A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to low accrual
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-31
Primary completion date: 2022-04-27
Completion date: 2023-06-08
Plan to share individual participant data: NO
Clinical trial NCT04657497: A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
Official title: A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)
Sponsor: Ono Pharmaceutical Co. Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 155.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-09
Primary completion date: 2021-03-26
Completion date: 2021-04-09
Plan to share individual participant data: NO
Clinical trial NCT05510245: A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
Official title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
Enrollment: 18.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-08-29
Primary completion date: 2023-07-20
Completion date: 2023-07-20
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05321862: Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.
Official title: Exploratory Study Evaluating the Relevance of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years Included in the Prospective IFM 2020-02.
Acronym: PENTI-MIDAS
Sponsor: Nantes University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: MIDAS inclusions terminated before first inclusion in PENTI-MIDAS
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-03-14
Primary completion date: 2023-05-04
Completion date: 2023-05-04
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03808168: Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia
Official title: Phase II Trial of Nivolumab Based Immunotherapy for the Treatment of High-Grade Cervical Dysplasia
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: FDA has withdrawn the IND application- requesting protocol changes
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-15
Primary completion date: 2019-06-01
Completion date: 2020-06-01
Plan to share individual participant data: NO
Clinical trial NCT05074433: A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Emerging SARS-CoV2 variants impacting susceptibility to study drug
Enrollment: 66.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-10-25
Primary completion date: 2022-05-18
Completion date: 2022-05-18
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Clinical trial NCT03925324: Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device
Acronym: STEM-VAD
Sponsor: Medstar Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of funding/Covid-19
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-03
Primary completion date: 2021-08-16
Completion date: 2021-08-16
Limitations and caveats: Due to lack of funding and COVID-19, the study was terminated early after 4 patients were recruited. This number is too small to perform any analysis
Clinical trial NCT03699033: Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Official title: A Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined With Carboplatin and Paclitaxel for Subjects With Stage IIIA or IIIB Non-Small Cell Lung Cancer
Sponsor: University of Toledo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No patients available
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-01
Primary completion date: 2020-10-01
Completion date: 2020-10-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05017610: Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Official title: A Single Arm Pilot Study to Evaluate the Safety and Feasibility of Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Per the PI-slow accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-20
Primary completion date: 2022-10-14
Completion date: 2022-10-14
Plan to share individual participant data: NO
Clinical trial NCT01121588: An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Official title: PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Termination of further treatment on the study due to the availability of commercial supply or a rollover study (NCT05160922) that will allow active subjects to continue receiving treatment.
Enrollment: 44.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-03-22
Primary completion date: 2023-09-07
Completion date: 2023-09-07
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03488251: PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Official title: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
Sponsor: Molecular Templates, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 8.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-08-20
Primary completion date: 2021-03-12
Completion date: 2021-03-12
Baseline population: Only data for Part 1: Cohort 1 is presented as study was terminated in Part 1 due to premature closure of the trial driven by an unfavorable risk benefit assessment in the concurrent monotherapy study; hence Part 1 (Cohort 2 and 3) and Part 2 were not initiated.
Plan to share individual participant data: NO
Clinical trial NCT02864147: Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Official title: Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel Prime and Pull Strategy
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 134.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-07-31
Primary completion date: 2022-05-24
Completion date: 2022-11-22
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04111107: Precision Medicine for Patients With Identified Actionable Mutations
Official title: Precision Medicine for Patients With Identified Actionable Mutations at Wake Forest Baptist Comprehensive Cancer Center (WFBCCC): A Pragmatic Trial-
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: PI left the institution and site decided not to continue the study
Enrollment: 45.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-22
Primary completion date: 2022-12-09
Completion date: 2023-02-09
Plan to share individual participant data: NO
Clinical trial NCT03275402: 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Official title: A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Sponsor: Y-mAbs Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Corporate business decision. Not due to safety or efficacy concerns.
Enrollment: 52.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-11
Primary completion date: 2023-06-02
Completion date: 2023-06-02
Limitations and caveats: The trial was terminated early due to a business strategy decision.
Plan to share individual participant data: NO
Clinical trial NCT03381196: A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection Who Are at Risk of Developing Complications
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Based on interim Analysis outcome being futile for FLZ3001; decision was taken to stop (early terminate) both FLZ3001/3002. There was no safety concern.
Enrollment: 553.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-21
Primary completion date: 2020-05-28
Completion date: 2020-08-24
Baseline population: The safety set (or all participants treated) includes all participants who received at least one dose of study drug and were analyzed by treatment arm as treated.
Limitations and caveats: As the study was terminated early after a pre-planned interim analysis which showed futility, the Sponsor decided not to perform the complete analysis planned per protocol. Hence, data was collected and analyzed for safety and selected efficacy parameters.
Clinical trial NCT04197986: Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Official title: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Acronym: PROOF302
Sponsor: QED Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The sponsor has decided to close the study due to the discontinuation of infigratinib development. The discontinuation of the study was not due to safety reasons.
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-11
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT04853524: A Study of JNJ-56136379 in Healthy Participants
Official title: A Phase 1, Open-label Study in Healthy Participants to Investigate the Effect of Multiple-dose JNJ-56136379 on the Single-dose Pharmacokinetics of Bictegravir, Emtricitabine, and Tenofovir Alafenamide
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-06
Primary completion date: 2021-06-15
Completion date: 2021-07-30
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04316624: A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Official title: A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Sponsor: Institute of Hematology & Blood Diseases Hospital, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-29
Primary completion date: 2023-02-08
Completion date: 2023-02-08
Plan to share individual participant data: NO